No Data
No Data
The innovative medical instruments industry is accelerating its reshaping, and Chuangtongqiao-B (02190) achieved profitability for the first time in 24H1.
The profit-making has started, and the business model of Chuangtong Bridge has been proven, with the valuation expected to be reshaped.
Press Release: Zylox-Tonbridge Reports Strong Interim Financial Results for 2024, Achieving Significant Growth and Profitability
Guichuangtong Bridge's mid-term performance in 2024: revenue increased by 59% YoY to 0.366 billion yuan, achieving net profit for the first time.
The midterm revenue increased by 59%, and Chunqiao achieved its first profit.
Guichuangtongqiao -B (02190) announced its interim performance, with adjusted surplus of 78.171 million yuan, turning losses into profits year-on-year.
Guichuangtongqiao-B (02190) announced its mid-term performance in 2024, with revenue of approximately 0.366 billion yuan, a year-on-year increase of 59 ...
Express News | Zylox-Tonbridge Medical Technology H1 Adjusted Net Income RMB 78.2 Million
Express News | Zylox-Tonbridge Medical Technology H1 Revenue RMB 366 Million
No Data
No Data